Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Kura Oncology ( (KURA) ).
On January 28, 2026, Kura Oncology’s board adopted amended and restated bylaws that significantly revise the company’s corporate governance framework, particularly around shareholder meetings, director nominations, and stockholder proposals. The changes tighten and clarify advance notice and disclosure requirements for shareholders seeking to nominate directors or bring other business before annual and special meetings, incorporate universal proxy rules, and require shareholders soliciting proxies to use a proxy card color other than white. The amended bylaws also adjust quorum and voting standards to focus on voting power and votes cast, refine procedures for postponing, rescheduling and adjourning stockholder meetings, and update notice and stockholder list practices to align with current Delaware corporate law. Further amendments expand and clarify indemnification and expense advancement protections for directors and officers, enhance the board’s flexibility on committee quorum and officer removal, and strengthen forum selection provisions, collectively reinforcing the company’s control over corporate procedures and potentially affecting how activists and other shareholders engage with its governance processes.
The most recent analyst rating on (KURA) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Kura Oncology stock, see the KURA Stock Forecast page.
Spark’s Take on KURA Stock
According to Spark, TipRanks’ AI Analyst, KURA is a Neutral.
The score is led by strong recent clinical/regulatory execution and commercialization milestones (FDA approval and first U.S. sale with a $135M payment), supported by reported cash runway through 2027. Offsetting this are still-large operating losses, shrinking equity, and only mixed near-term technical momentum, while valuation metrics are not very informative due to negative earnings.
To see Spark’s full report on KURA stock, click here.
More about Kura Oncology
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for the treatment of cancer, leveraging targeted oncology approaches to address molecularly defined patient populations in the oncology market.
Average Trading Volume: 1,753,863
Technical Sentiment Signal: Strong Sell
Current Market Cap: $737M
For a thorough assessment of KURA stock, go to TipRanks’ Stock Analysis page.